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Abstract 
Background: Bone marrow mesenchymal stem cells (BMMSCs) and bone marrow mononuclear cells (BMMNCs) are 
both used to treat spastic cerebral palsy. However, the differences in therapeutic effect remain unknown.
Methods: A total of 105 patients with spastic cerebral palsy were enrolled and randomly assigned to three groups: 
the BMMSC group, the BMMNC group and the control group. Patients in both transplantation groups received four 
intrathecal cell injections. Patients in the control group received Bobath therapy. The gross motor function measure 
(GMFM) and the fine motor function measure (FMFM) were used to evaluate the therapeutic efficacy before trans-
plantation and 3, 6, and 12 months after transplantation.
Results: Three months after cell transplantation, scores in the A dimension of GMFM and the A and C dimensions 
of FMFM scores in the BMMSC group are all higher than those of the BMMNC and the control groups (P < 0.05). Six 
months after cell transplantation, scores in the A, B dimensions of GMFM and the A, B, C, D, and E dimensions of FMFM 
scores in the BMMSC group are higher than those of the BMMNC and the control groups (P < 0.05). Twelve months 
after cell transplantation, scores in the A, B, and C dimensions of GMFM and the A, B, C, D, and E dimensions of FMFM 
scores in the BMMSC group are all higher than those of the BMMNC and the control groups (P < 0.05). No obvious 
adverse effects were investigated during follow-up.
Conclusions: BMMSC transplantation for the treatment of cerebral palsy is safe and feasible, and can improve gross 
motor and fine motor function significantly. In addition, compared with BMMNC, the motor function of children 
improved significantly in terms of gross motor and fine motor functions.
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Background
Spastic cerebral palsy (CP) is a type of non-progressive 
brain disorder resulting from various brain injuries that 
occurred in the period from conception to 1 month after 
childbirth. Its main clinical manifestations are motor 
dysfunction, abnormal posture, and, often, blindness, 
deafness, epilepsy, mental retardation, and other symp-
toms. The causes of spastic CP include periventricular 
leukomalacia, cerebral dysplasia, hypoxia and intrapar-
tum asphyxia, intracranial haemorrhage and multiple 
other factors [1]. According to statistics, 1.5–2.5 children 
per 1000 of the population in developed countries, have 
spastic CP, and this can be even higher in developing 
countries [2]. Such a high incidence has placed a heavy 
burden on families and society.
At present, the treatment of children with spastic CP 
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therapy, rehabilitation training, language training, ortho-
paedic surgery, denervation, and intramuscular injection 
of botulinum toxin and other symptomatic treatment, 
but the effects are unsatisfactory [3]. In recent years, 
cell transplantation in the treatment of spastic CP has 
resulted in positive effects in both animal experiments 
and clinical studies [4–7]. Among the many kinds of stem 
cells, bone marrow mesenchymal stem cells (BM-MSCs) 
have become a popular form of seed cell transplantation 
because of their convenience, low immunogenicity, and 
amplification ability [8]. Our previous clinical experi-
ments prove that BMMSC transplantation can effec-
tively improve the symptoms of spastic CP, including 
motor function, language and cognition [9–11]. Recently, 
research has also confirmed that treatment with bone 
marrow mononuclear cell (BMMNC) transplantation 
has also had positive and significant effects for spas-
tic CP [4]. These encouraging results indicate that cell 
transplantation for the treatment of spastic CP has broad 
prospects in the field. However, whether BMMSC and 
BMMNC from bone marrow have any difference of cura-
tive effect for the treatment of spastic CP remains unre-
ported. Therefore, to understand whether there are any 
significant differences between BMMSC and BMMNC 
transplantation, and between BMMSC and BMMNC 
and traditional rehabilitation treatment for children with 
spastic CP, we designed this experiment.
Methods
Study design
This study is a prospective, randomised, parallel group 
study. The study was approved by the General Hospital 
of Chinese People’s Armed Police Forces Medical Eth-
ics Committee and has been registered in WHO (regis-
tration number CHiCTR-TRC-12002568). The patients’ 
families signed informed consent and understood the 
purpose and the significance of this study, the possi-
ble benefits and the risks of side effects (e.g., pain, fever, 
infection, worsening of motor function and other unpre-
dictable side effects and the corresponding remedies). 
Figure 1 summarises the experimental design.
Patients
This study involved 105 CP patients who were enrolled 
from May 1, 2010, to October 31, 2012. Patients were 
randomly assigned into the BMMSC group, the BMMNC 
group or the control group in a 1:1:1 ratio. The ran-
domisation table was generated by SAS software. After 
randomisation, the study processes were blinded to the 
patients in the BMMSC and BMMNC groups, partici-
pant surgeons, coordinators, and the investigators who 
were responsible for patient assessment.
The case inclusion criteria were as follows: (1) chil-
dren 6 to 150 months of age diagnosed with spastic CP; 
(2) gross motor function classification system (GMFCS) 
score between levels II and V; (3) no interferences due 
to other related treatments within 3 months prior to the 
enrolment and during the treatment, such as rehabilita-
tion, traditional Chinese medicine, and surgery; and (4) 
parents voluntarily accepted UCMSC transplantation 
therapy and agreed to cooperate with follow-up studies. 
The case exclusion criteria were as follows: (1) patients 
with a history of severe allergic or autoimmune disease; 
(2) patients with a history of intractable seizures; (3) 
patients with AIDS, hepatitis, or positive serology for 
syphilis; (4) patients with hereditary metabolic diseases 
of the nervous system; (5) patients with tumours and/or 
blood disease history; and (6) patients who were rejected 
due to other serious diseases, such as brain tumours 
or mental and psychological disorders. All patients 
were placed randomly into three groups. The BMMSC 
group consisted of 19 boys and 16 girls with a mean 
age of 49.55  ±  31.95  months (range, 6–132  months). 
The BMMNC group consisted of 20 boys and 15 girls 
with a mean age of 49.10  ±  29.39  months (range, 
10–150 months). The control group included 35 patients 
with spastic CP who were treated with rehabilitation 
therapy. The control group consisted of 19 boys and 16 
girls with a mean age of 49.26  ±  31.31  months (range, 
7–140  months). The gross motor function classification 
system (GMFCS) was used to classify the severity of the 
disease, the GMFCS levels for all patients were II–V.
Cell preparation
Preparation of human BMMNCs
The parents of the patients signed informed consent. 
Patients were taken into the operating room, and placed 
in the left decubitus position and with their right poste-
rior iliac crests exposed. After conventional iodine alco-
hol disinfection and local anesthesia with Lidocaine, a 
medullo-puncture needle was used to vertically penetrate 
the cortical bone into the bone marrow cavity. A heparin 
saline mixture (100  U/mL) of 5  mL in a 20  mL syringe 
was connected to the bone needle and 15  mL of bone 
marrow was extracted, for a total of 60  mL. After mix-
ing well, and under strict aseptic conditions, 30 mL of the 
diluted bone marrow was added to 15 mL of Ficoll-Paque 
solution in every 50 mL centrifuge tube. Density-gradient 
centrifugation was performed according to the manu-
facturer’s instructions. Mononuclear cells were collected 
and washed twice in saline. If the children were crying, 
screaming, or moving in a restless motion to the extent 
that the surgeon could not proceed, chloral hydrate was 
used orally, or anally 1 h before the operation in a dosage 
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according to the child’s weight (50 mg/kg) or by the body 
surface area (1.5 g/m2).
Preparation of human BMMSCs
BMMSCs were prepared as previously described [9]. 
Briefly, made from bone marrow MNC and contain-
ing 10% foetal bovine serum and Dulbecco’s modified 
Eagle’s medium, the cell suspension with 2  ×  106 to 
4  ×  106/cm2 cells was seeded in culture flasks, and 
incubated at 37 °C in a humidified tissue culture incu-
bator containing 5% CO2 and 95% air, with a change 
of culture medium every 3–5  days. After 10  days in 
culture, the adherent cells were trypsinised and pas-
saged into a new culture bottle for further expansion. 
The BM-MSCs harvested from passage three were 
frozen before characterising MSC markers with flow 
cytometry. Flow cytometry results showed that ≥95% 
of cells expressed CD105, CD73, CD44, whereas the 
expression of CD45, CD34, CD31, CD146 and HLA-
DR was 2% or less. One week before transplantation, 
the cryopreserved BM-MSCs were thawed for further 
culture and expansion. BM-MSCs between passages 4 
and 6 were used for transplantation after character-
ising MSC markers with flow cytometry. Made after 
bone marrow MNC containing 10% foetal bovine 
serum and Dulbecco’s modified Eagle’s medium, the 
cell suspension with 2 × 106 to 4 × 106/cm2 cells was 
seeded in culture flasks.
Fig. 1 Experimental design
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Cell transplantation
All of the patients were hospitalised and received four 
cell transplantations at an interval of 3–4 days. The pro-
tocol was performed as previously described [12]. In 
brief, a lumbar puncture was performed in the lumbar 
3–4 or lumbar 4–5 intervertebral space. After the punc-
ture needle had been confirmed to penetrate into the 
subarachnoid space, 2  mL of stem cell suspension was 
slowly injected into the space. Each time, the number of 
cells used was 1 × 106/kg body weight.
Intervention in control group
We used Bobath therapy (neuro-developmental treatment) 
as the unified method of treatment in the control group. 
The specific method is consistent with that of Knox Vir-
ginia et al. [13] including the following: (1) reflex inhibition 
(2) adjusting the key point (3) facilitating postural reflex to 
induce the maximal potential of the child without overexer-
tion, form the movement posture of functional activity, and 
learn and comprehend the experience, and (4) percussion.
The patients in the control group received treatment 
in every 2  days, with a total course of 3  weeks. The 
Bobath method was administered by two skilled reha-
bilitation therapists.
Assessment of efficacy
The gross motor function measure (GMFM) and fine 
motor function measure (FMFM) were used to evaluate 
the efficacy of cell therapy. All patients were evaluated 
at admission and followed-up at 3, 6 months, and 1 year 
after transplantation. All the evaluations were performed 
by two professional rehabilitation physicians who were 
blind to the study.
Statistical analysis
All of the data are shown as the mean ± standard devia-
tion (SD). Comparisons between before and after trans-
plantation variables for each group were based on a 
paired t test. The GMFM and FMFM scores were com-
pared among the three groups using the Student–New-
man–Keuls test following one-way analysis of variance 
(ANOVA). A significant difference was indicated by 
P  <  0.05. All statistical analyses were performed using 
SPSS (Version 16.0 for Windows, SPSS, Chicago, IL).
Results
Two children in the BMMSC group and one child in the 
BMMNC group left the experiment due to their parent 
withdrawal. In all, there are 33 patients in the BMMSC 
group (18 boys and 15 girls), and 34 patients (18 boys and 
16 girls) in the BMMNC group completed the experi-
ment. The general details, as well as GMFM and FMFM 
scores are provided in Additional file 1, Tables 1 and 2.
Baseline comparison
In comparison of the baseline of GMFM, FMFM, and 
dimensions among the BMMCS group, BMMNS group, 
and the control group, the differences were not statisti-
cally significant (P > 0.05).
Changes in gross motor function of children in the BMMSC 
group
Three months after cell transplantation, compared with 
the score before transplantation (Table 1), scores of A, B, 
and C dimensions of GMFM have significant improve-
ment (P < 0.05 or P < 0.01). And, the total score of GMFM 
also improved significantly (P < 0.01). Scores of D and E 
dimensions also showed some improvement, but not sig-
nificantly (P > 0.05). Six months after cell transplantation, 
compared with the score before transplantation, scores 
of A, B, C, and D dimensions of GMFM have significant 
improvement (P < 0.05 or P < 0.01). And, the total score 
of GMFM also improved significantly (P < 0.01). Scores 
of E dimensions have also shown some improvement, 
but not significantly (P > 0.05). Twelve months after cell 
transplantation, compared with the score before trans-
plantation, scores of A, B, C, D and E dimensions and 
the total score of GMFM have significant improvement 
(P < 0.05 or P < 0.01).
Changes in gross motor function of children in the BMMNC 
group
Three months after cell transplantation, compared 
with the score before transplantation (Table  1), scores 
of A, B, and C dimensions of GMFM have significant 
improvement (P  <  0.05). And the total score of GMFM 
also improved significantly (P  <  0.05). Scores of D and 
E dimensions have also shown some improvement, but 
not significantly (P  >  0.05). Six months after cell trans-
plantation, compared with the score before transplanta-
tion, scores of A, B, and C dimensions of GMFM have 
significant improvement (P  <  0.05). And the total score 
of GMFM also improved significantly (P < 0.01). Scores 
of D and E dimensions have also shown improvement, 
but not significantly (P > 0.05). Twelve months after cell 
transplantation, compared with the score before trans-
plantation, scores of A, B, and C dimensions and the total 
score of GMFM have significant improvement (P < 0.05 
or P < 0.01). Scores of D and E dimensions had no signifi-
cant improvement (P > 0.05).
Changes in gross motor function of children in the control 
group
Three and six months after rehabilitation therapy 
(Table  1), scores of all dimensions and the total of 
GMFM scores both have shown some improvement, 
but not significantly (P > 0.05). Twelve months after cell 
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transplantation, compared with the score before trans-
plantation, scores of A, B, and C dimensions and the total 
score of GMFM have significant improvement (P < 0.05 
or P < 0.01). Scores of D and E dimensions had no signifi-
cant improvement (P > 0.05).
Comparison of GMFM score among groups within each 
interval
Three months after each intervention, dimension A of the 
BMMSC group gained significant statistical difference 
compared with the other two groups (P < 0.05), whereas 
the difference of A dimension between the BMMNC 
group and the control is not significant (P  >  0.05). Dif-
ferences of dimension C between the BMMSC group and 
the BMMNC group, and the BMMNC group and the 
control group, are not significant (P > 0.05), whereas the 
difference between the BMMSC group and the control 
group is significant (P  <  0.05); The differences of the B, 
D and E dimensions and GMFM total scores among the 
three groups are not significant (P > 0.05).
Six months after each intervention, dimensions A and B 
and the GMFM total scores of the BMMSC group gained 
significant statistical difference compared with the other 
two groups (P < 0.05), whereas the difference of A and B 
dimensions between the BMMNC group and the control 
is not significant (P > 0.05). The difference of dimension 
C between the BMMSC group and the BMMNC group, 
and the BMMNC group and the control group, is not sig-
nificant (P > 0.05), whereas the difference of C dimension 
between the BMMSC group and the control group is sig-
nificant (P < 0.05). The differences of D and E dimensions 
among the three groups are not significant (P > 0.05).
Twelve months after each intervention, dimension 
A, B, and C, GMFM total scores of the BMMSC group, 
gained significant statistical difference compared with 
the other two groups (P < 0.05), whereas the differences 
between the BMMNC group and the control are not sig-
nificant (P > 0.05). The differences of D and E dimensions 
among the three groups are not significant (P > 0.05).
Changes in fine motor function of children in the BMMSC 
group
Three months after cell transplantation, compared 
with the score before transplantation (Table  2), scores 
of A, B, C, and D dimensions of FMFM in the BMMSC 
group patients have significant improvement (P  <  0.05 
or P  <  0.01). And, the total score of FMFM also 
improved significantly (P < 0.01). Scores of E dimension 
have also gained some improvement, but not signifi-
cantly (P  >  0.05). Six months after cell transplantation, 
Table 1 GMFM scores of the three groups after intervention (x¯± s)
** Compared with scores before transplantation/Bobath therapy, P < 0.01
* Compared with scores before transplantation/Bobath therapy, P < 0.05
△  Compared with scores 3 month after transplantation, P < 0.05
GMFM-domain Baseline 3 months 6 months 12 months
BMMMSC group
 A 31.36 ± 7.24 36.70 ± 7.11** 38.39 ± 6.54** 39.73 ± 6.77**
 B 31.97 ± 9.76 36.39 ± 9.65** 40.18 ± 8.60** 41.55 ± 8.60**
 C 20.61 ± 3.55 23.39 ± 3.78* 24.21 ± 3.76* 25.30 ± 3.97**
 D 5.21 ± 8.15 8.42 ± 9.59 9.58 ± 10.40* 10.18 ± 10.37*
 E 6.06 ± 10.91 8.33 ± 11.64 9.64 ± 12.44 10.27 ± 12.39*
 Total 95.21 ± 32.69 113.15 ± 34.93** 122 ± 35.50** 127.03 ± 35.80**△
BMMNC group
 A 31.67 ± 6.77 32.29 ± 6.72* 33.44 ± 6.67* 35.29 ± 6.54*
 B 32.09 ± 9.65 33.12 ± 9.55* 34.38 ± 9.89* 36.29 ± 9.86*
 C 20.65 ± 3.39 21.71 ± 3.52* 22.76 ± 3.41* 23.85 ± 3.55*
 D 5.21 ± 7.99 5.71 ± 8.09 6.62 ± 8.08 8.09 ± 8.56
 E 6.07 ± 9.99 6.65 ± 10.06 7.56 ± 10.26 8.38 ± 10.61
 Total 95.68 ± 30.79 99.47 ± 30.89* 104.76 ± 31.39** 111.91 ± 31.68**
Control group
 A 31.46 ± 6.95 31.97 ± 6.89 32.49 ± 6.50 32.91 ± 6.18*
 B 32.66 ± 9.22 33.2 ± 8.91 33.71 ± 8.80 34.34 ± 8.62*
 C 20.71 ± 3.78 21.06 ± 3.93 21.66 ± 3.92 22.23 ± 4.02*
 D 4.91 ± 7.13 5.26 ± 7.32 5.83 ± 7.37 6.37 ± 7.68
 E 5.54 ± 9.13 5.86 ± 9.04 6.17 ± 9.08 6.66 ± 9.00
 Total 95.26 ± 29.19 97.34 ± 28.96 99.86 ± 28.48* 102.51 ± 28.30**
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compared with the score before transplantation, scores of 
A, B, C, D and E dimensions and the total score of FMFM 
have significant improvement (P  <  0.05 or P  <  0.01). 
Twelve months after cell transplantation, compared with 
the score before transplantation, scores of A, B, C, D and 
E dimensions and the total score of FMFM have signifi-
cant improvement (P < 0.05 or P < 0.01).
Changes in fine motor function of children in the BMMNC 
group
Three months after cell transplantation, compared with 
the score before transplantation (Table  2), the score of 
A dimension of FMFM in the BMMNC group patients 
has significant improvement (P  <  0.05). Scores of B, C, 
D and E dimensions, as well as the FMFM total score, 
also gained some improvement, but not significantly 
(P  >  0.05). Six months after cell transplantation, com-
pared with the score before transplantation, scores of A, 
B, C, D, and E dimensions and the total score of FMFM 
have significant improvement (P  <  0.05 or P  <  0.01).
Twelve months after cell transplantation, compared with 
the score before transplantation, scores of A, B, C, D, and 
E dimensions and the total score of FMFM have signifi-
cant improvement (P < 0.05 or P < 0.01).
Changes in fine motor function of children in the control 
group
Three months after rehabilitation therapy, compared 
with the score before intervention (Table 2), the score of 
A dimension of FMFM in the control group patients has 
significantly improved (P < 0.05). Scores of B, C, D, and E 
dimensions, together with FMFM total score, have gained 
some improvement, but not significantly (P  >  0.05). Six 
months after rehabilitation therapy, compared with the 
score before intervention, the score of A dimension has 
significant improvement (P < 0.05). Scores of B, C, D, and 
E dimensions, as well as FMFM total score, have received 
some improvement, but not significantly (P > 0.05).Twelve 
months after cell transplantation, scores of A and the total 
score of FMFM have significant improvement (P < 0.05).
Comparison of FMFM score among each group and each 
interval
Three months after each intervention, dimension A and 
C of the BMMSC group gained significant statistical dif-
ference compared with the other two groups (P < 0.05), 
whereas the difference of A and C dimensions between 
the BMMNC group and the control group is not signifi-
cant (P > 0.05). The differences of B, D, and E dimensions 
Table 2 FMFM scores of three groups after intervention (x¯± s)
** Compared with scores before transplantation/Bobath therapy, P < 0.01
* Compared with scores before transplantation/Bobath therapy, P < 0.05
△  Compared with scores 3 month after transplantation, P < 0.05
FMFM-domain Baseline 3 months 6 months 12 months
BMMMSC group
 A 9.88 ± 2.81 12.03 ± 2.48** 15.00 ± 2.40** 17.58 ± 2.41**
 B 10.15 ± 3.63 12.27 ± 3.28** 15.64 ± 3.36** 17.67 ± 3.49**
 C 7.24 ± 4.19 10.55 ± 4.62** 13.70 ± 3.40** 15.58 ± 4.47**
 D 6.36 ± 5.15 9.21 ± 6.20* 12.76 ± 7.37** 14.82 ± 7.10**
 E 6.82 ± 6.47 8.88 ± 8.29 12.67 ± 8.82* 13.76 ± 8.76*
 Total 40.45 ± 18.31 52.94 ± 20.94** 69.76 ± 21.67**△ 79.39 ± 21.95**△
BMMNC group
 A 9.91 ± 2.85 10.47 ± 2.94* 11.15 ± 3.02* 11.94 ± 2.96*
 B 10.14 ± 3.52 11.06 ± 3.35 12.18 ± 3.41* 12.68 ± 3.30*
 C 7.24 ± 4.11 7.88 ± 4.04 8.53 ± 4.03* 9.38 ± 4.20*
 D 6.47 ± 4.91 6.85 ± 5.03 7.88 ± 5.25* 8.94 ± 5.55*
 E 6.79 ± 6.23 7.76 ± 6.80 8.65 ± 7.03* 9.65 ± 7.19*
 Total 40.56 ± 17.57 44.03 ± 17.99 48.38 ± 18.47* 52.59 ± 18.89**
Control group
 A 9.83 ± 2.86 10.31 ± 2.54* 10.71 ± 2.67* 11.11 ± 2.89*
 B 10.03 ± 3.68 10. 60 ± 3.99 11.03 ± 4.07 11.34 ± 4.01
 C 7.26 ± 4.23 7.74 ± 4.56 7.94 ± 4.56 8.46 ± 4.13
 D 6.46 ± 4.97 6.86 ± 4.95 7.26 ± 5.00 7.54 ± 5.12
 E 6.86 ± 6.40 7.40 ± 6.63 7.83 ± 6.83 8.26 ± 6.96
 Total 40.43 ± 15.88 42.91 ± 15.84 44.77 ± 16.27 46.71 ± 16.07*
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and FMFM total scores among the three groups are not 
significant (P > 0.05).
Six months after each interventions, dimension A, B, C, 
D, and E and FMFM total scores of the BMMSC group 
gained significant statistical differences, compared with 
the other two groups (P < 0.05), whereas these differences 
between the BMMNC group and the control group are 
not significant (P > 0.05).
Twelve months after each intervention, dimension A, 
B, C, D, and E and FMFM total scores of the BMMSC 
group gained significant statistical differences, compared 
with the other two groups (P < 0.05), whereas these dif-
ferences between the BMMNC group and the control 
group are not significant (P > 0.05).
Adverse effects
The side effects of cell transplantation included the follow-
ing: (1) fever: some patients experienced mild and moder-
ate fever, which generally occurred on the first operative 
day and spontaneously recovered to normal levels, and the 
incidence was 8.8% (3/34) in the BMMNC group and 6.1% 
(2/33) in the BMMSC group; (2) low intracranial pressure 
reactions: the symptoms included nausea, vomiting, and 
headache. All of these symptoms were relieved or disap-
peared when the patients lay in bed in a supine position 
without a pillow and were treated with intravenous saline 
infusions. The incidence was 17.6% (6/34) in the BMMNC 
group and 12.1% (4/33) in the BMMSC group.
Discussion
Spastic CP is a motor disorder with the feature of deteri-
orating motor nerve growth and permanent, irreversible 
limitation of activity. Due to the complexity of its patho-
genesis and treatment,as well as its irreversibility,spastic 
CP has always been a challenge to CP patients, families, 
and the clinicians who treat them all over the world [14]. 
In recent years, along with the development of cell tech-
nology, a number of clinical studies have shown that stem 
cell transplantation in the treatment of traumatic brain 
injury [12], cerebral haemorrhage [15], stroke [16], spi-
nal cord injury [17], ataxia [5, 18, 19] and many other 
kinds of diseases of the nervous system is safe and effec-
tive. These encouraging results open a new field for the 
treatment of CP. In addition, because of the plasticity of 
the childhood brain, this point in development also pro-
vides a great opportunity for the cell treatment of spastic 
CP [18]. There have been clinical studies using umbilical 
cord derived mesenchymal stem cells [11], embryonic 
stem cells [6], umbilical cord blood stem cells [20], bone 
marrow mesenchymal stem cells [9] and bone marrow 
mononuclear cells [4] for the treatment of spastic CP, and 
these treatments have achieved a certain effect. Among 
them, the BMMSCs and BMMNCs, owing to the ease of 
acquisition, no risk of rejection, and no ethical restric-
tions, have been widely used in the treatment of various 
neurological diseases. Because the two kinds of cells orig-
inate from the same source, and differ in the method of 
culturing, we compared and analysed the effect between 
autologous BMMSCs and autologous BMMNCs for the 
treatment of spastic CP, to guide future treatment.
This study concludes, in terms of gross motor function, 
3  months after transplantation, the BMMSC group and 
the BMMNC group begin to gain significant improve-
ments (A, B, and C dimensions and GMFM total scores). 
These findings are the same as those for previous studies 
(Alok Sharma et  al. [4] using BMMNCs; Guojun Chen 
et al. using neural stem cell-like cells derived from autolo-
gous BMMSCs) about the timing of outcomes [14]. Six 
months after the intervention, A and B dimensions and 
GMFM total scores in the BMMSC group were better 
than those for the other two groups, whereas the differ-
ences between the BMMNC group and the control group 
are not significant. Twelve months after the intervention, 
A, B, and C dimensions and GMFM total scores in the 
BMMSC group were better than those for the other two 
groups. The results indicate that, 3 months after transplan-
tation, in gross motor skills, BMMSC and BMMNC could 
significantly improve the gross motor function of children 
with spastic CP, and the outcomes are better than those 
for the rehabilitation group. However, with the extension 
of time, improvement of the gross motor function of the 
BMMSC group, especially in A, B, and C dimensions and 
the total score of GMFM, is more persistent than that of 
the BMMNC group. Six and twelve months after trans-
plantation, there is no difference between the BMMNC 
group and the rehabilitation group, which also indicates 
that BMMNCs have a poor persistence in improving gross 
motor function. In terms of fine motor function, we also 
found that 6  months after treatment, considering each 
dimensions and total score of FMFM, the BMMSC group 
was better than the BMMNC and the rehabilitation treat-
ment group, which further proved that the continuity of 
improvement of BMMSC for the motor function of chil-
dren with spastic CP is better than BMMNC.
As for the insignificant improvement of D and E 
dimensions, several possibilities may have caused this 
phenomenon: (1) From the A to E dimension, the cor-
responding action of muscle strength and coordination 
required to complete the task is gradually increasing; 
thus, the children’s improvement from A dimension 
gradually expanded to E dimension. (2) Because many 
patients were infants or young children, and are thus 
not quite capable of completing the tasks in the D and E 
dimensions, the resulting D and E scores showed no sig-
nificant difference before and after transplantation. The 
related research needs to further confirm our results.
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Most of the treatment mechanisms of cell transplanta-
tion were studied through animal experiment, and there 
are three major mechanisms: (1) regeneration and differ-
entiation mechanism: the transplanted cells differentiate 
into corresponding cells such as neurons, oligodendro-
cytes or astrocytes by homing to the damaged area [21, 
22]; (2) paracrine mechanism: the transplanted cells can 
secrete a variety of cytokines, such as neurotrophic fac-
tors, anti-inflammatory cytokines, and angiogenic fac-
tors. BMMSCs have stronger ability of secretion than do 
BMMNCs [23, 24]; and (3) Immune regulation mecha-
nism: mesenchymal stem cells (MSCs) can regulate the 
body’s immune system and inhibit the abnormal immune 
response [25, 26]. We believe that the major treatment 
mechanism of the transplanted stem cells are the parac-
rine mechanism [27, 28] and the vascular regeneration 
mechanism [24], especially in that human MSC subpopu-
lations express a variety of neuro-regulatory molecules 
and promote neuronal cell survival and neurogenesis 
[29]. In addition, studies showed that BMMSCs are bet-
ter than BMMNCs in both the capacity and the ability of 
paracrine and differentiation [23]. Many studies obtained 
the same conclusion in different types of disease treated 
with BMMSCs and BMMNCs. Lu D demonstrated that 
BMMSC therapy may be better tolerated and more effec-
tive than BMMNCs for increasing lower limb perfusion 
and promoting foot ulcer healing in diabetic patients 
with critical limb ischemia [30]. The Mazo M study also 
showed that MSC provides a long-term superior benefit 
over whole BMMNC transplantation in a rat model of 
chronic myocardial infarction [31]. These mechanisms 
partly explain why BMMSC has a better therapeutic 
effect than BMMNC in children with spastic CP.
Many clinical studies reported that the therapeutic 
effect of BMMSC and BMMNC is not associated with 
serious complications [4, 20]. In this study, no children 
in either of the two cell transplantation groups had any 
serious adverse reactions; some did experience low fever 
and intracranial pressure, which is the same as found in 
other research studies. We found that patients treated 
with BMMSCs and BMMNCs had no serious adverse 
reactions. Two patients (2/33) in the BMMSC group 
and three patients (3/34) in the BMMNC group had a 
low fever, while the number in BMMNC group is three 
(3/34). Low intracranial pressure symptoms are associ-
ated with lumbar surgery, and are not associated with cell 
transplantation.
Conclusions
Through this research, we further confirmed that BM-
MSCs transplantation for the treatment of CP is safe and 
feasible, and can improve gross and fine motor function 
significantly in children with spastic CP. And, compared 
with the results of BMMNC treatment, BMMSC treat-
ment significantly improved the gross and fine motor 
function of children with spastic CP children improved 
significantly in terms of gross motor or the fine motor 
functions.
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